Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, MD, Eva Hoster, Martin H. Dreyling, Roswitha Forstpointner, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Rudolf Schmits, Bernd Metzner, Michael Hallek, MD, Eva Lengfelder, Wolfgang Hiddemann, Michael Unterhalt

Blood (2009) 114 (22): 3706.

https://doi.org/10.1182/blood.V114.22.3706.3706

Published: 2009

Journal Articles

Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

Wolfgang Hiddemann, Christian Buske, Michael Kneba, MD, PhD, Martin Dreyling, Norbert Schmitz, Eva Lengfelder, Rudolf Schmits, Marcel Reiser, Bernd Metzner, Michael Unterhalt, PhD

Blood (2008) 112 (11): 772.

https://doi.org/10.1182/blood.V112.11.772.772

Published: 2008

Journal Articles

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Blood (2008) 112 (11): 2599.

https://doi.org/10.1182/blood.V112.11.2599.2599

Published: 2008

Journal Articles

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Blood (2005) 106 (12): 3725–3732.

https://doi.org/10.1182/blood-2005-01-0016

Published: 2005

Journal Articles

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Blood (2005) 106 (11): 13.

https://doi.org/10.1182/blood.V106.11.13.13

Published: 2005

Journal Articles

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

Martin Dreyling, Georg Lenz, Eva Hoster, Achiel Van Hoof, Christian Gisselbrecht, Rudolf Schmits, Bernd Metzner, Lorenz Truemper, Marcel Reiser, Hjalmar Steinhauer, Jean-Michel Boiron, Marc A. Boogaerts, Ali Aldaoud, Vittorio Silingardi, Hanneke C. Kluin-Nelemans, Joerg Hasford, Reza Parwaresch, Michael Unterhalt, Wolfgang Hiddemann

Blood (2005) 105 (7): 2677–2684.

https://doi.org/10.1182/blood-2004-10-3883

Published: 2005

Journal Articles

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, MD, PhD, Roswitha Forstpointner, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, PhD, Rudolf Schmits, MD, PhD, Bernd Metzner, MD, Marcel Reiser, MD, Eva Lengfelder, MD, PhD, Bernhard Woermann, MD, PhD, Hariett Harder, MD, Susanna Hegewisch-Becker, MD, PhD, Wolfgang Berdel, MD, PhD, Georg Hess, MD, Hartmut Eimermacher, MD, Ali Aldaoud, MD, Manfred Planker, MD, Reza Parwaresch, MD, PhD, Martin Dreyling, MD, PhD, Michael Unterhalt, MD

Blood (2004) 104 (11): 161.

https://doi.org/10.1182/blood.V104.11.161.161

Published: 2004

Journal Articles

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL

Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Bernd Metzner, Dirk Hasenclever, Norbert Schmitz, Bertram Glass, Christian Rübe, Markus Loeffler, the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Blood (2004) 104 (3): 626–633.

https://doi.org/10.1182/blood-2003-06-2094

Published: 2004

Journal Articles

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rübe, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Hartmut Eimermacher, Dirk Hasenclever, Norbert Schmitz, Markus Loeffler, the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Blood (2004) 104 (3): 634–641.

https://doi.org/10.1182/blood-2003-06-2095

Published: 2004

Journal Articles

Hodgkin and Reed-Sternberg cell–associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells

Ugur Sahin, Frank Neumann, Özlem Türeci, Rudolf Schmits, Franck Perez, Michael Pfreundschuh

Blood (2002) 100 (12): 4139–4145.

https://doi.org/10.1182/blood.V100.12.4139

Published: 2002

Journal Articles

CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity

Rudolf Schmits, Jorge Filmus, Nicole Gerwin, Giorgio Senaldi, Friedemann Kiefer, Thomas Kundig, Andrew Wakeham, Arda Shahinian, Charles Catzavelos, Janusz Rak, Caren Furlonger, Arsen Zakarian, John J.L. Simard, Pamela S. Ohashi, Christopher J. Paige, Jose C. Gutierrez-Ramos, Tak W. Mak

Blood (1997) 90 (6): 2217–2233.

https://doi.org/10.1182/blood.V90.6.2217

Published: 1997

NARROW

Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).

Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Hodgkin and Reed-Sternberg cell–associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells

CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only